[A22-102] Pertuzumab/trastuzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2023
Project no.: A22-102
Commission: Commission awarded on 29.09.2022 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
adjuvant treatment of adult patients with HER2-positive, early breast cancer at high risk of recurrence (node-positive or hormone receptor-negative)
indication of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.